Market Newsdesk

News Summary:

• NVIDIA DLSS 5, arriving this fall, introduces a real-time neural rendering model that infuses pixels with photoreal lighting and materials.
• DLSS 5 is the company’s most significant breakthrough in computer graphics since the debut of real-time ray tracing in 2018.
• DLSS 5 will be supported by the industry’s biggest publishers and game developers, including Bethesda, CAPCOM, Hotta Studio, NetEase, NCSOFT, S-GAME, Tencent, Ubisoft and Warner Bros. Games.

SAN JOSE, Calif., March 16, 2026 (GLOBE NEWSWIRE) — NVIDIA today unveiled NVIDIA DLSS 5, the company’s most significant breakthrough in computer graphics since the debut of real-time ray tracing in 2018.

DLSS 5 introduces a real-time neural rendering model that infuses pixels with photoreal lighting and materials. Bridging the divide between rendering and reality, DLSS 5 empowers game developers to deliver a new level of photoreal computer graphics previously only achieved in Hollywood visual effects.

“Twenty-five years after NVIDIA invented the programmable shader, we are reinventing computer graphics once again,” said Jensen Huang, founder and CEO of NVIDIA. “DLSS 5 is the GPT moment for graphics — blending handcrafted rendering with generative AI to deliver a dramatic leap in visual realism while preserving the control artists need for creative expression.”

Bridging the Cinematic Gap

Since the dawn of NVIDIA GeForce™, NVIDIA has strived to deliver the graphics horsepower required for game developers to create incredible, realistic worlds — where lighting, reflections and shadows obey the laws of nature.

From programmable shaders with GeForce 3 in 2001, to CUDA^® with GeForce 8800 GTX™ in 2006, to real-time ray tracing with GeForce RTX™ 2080 Ti in 2018, to path tracing and neural shaders with GeForce RTX 5090 in 2025, NVIDIA has delivered major architectural innovations and a massive 375,000x increase in compute to meet this challenge.

However, the rendering horsepower available to a 16-millisecond game frame remains a tiny fraction of that available to a photoreal Hollywood VFX frame, which can take minutes to hours to render. Real-time rendering cannot bridge the gap to photorealism through brute force alone.

DLSS was released in 2018 as an AI technology to boost performance, first by upscaling resolution and then by generating entirely new frames. It has been integrated in over 750 games, becoming a gold standard for the industry.

Launched at CES this year, DLSS 4.5 uses AI to draw 23 out of every 24 pixels seen on the screen. Today, DLSS is evolving beyond performance to transform visual fidelity in games.

Video AI models have rapidly learned to generate photoreal pixels, but they run offline, are difficult to precisely control and often lack predictability, with every new prompt generating bespoke content. For games, pixels must be deterministic, delivered in real time and tightly grounded in the game developer’s 3D world and artistic intent.

DLSS 5 takes a game’s color and motion vectors for each frame as input, and uses an AI model to infuse the scene with photoreal lighting and materials that are anchored to source 3D content and consistent from frame to frame. DLSS 5 runs in real time at up to 4K resolution for smooth, interactive gameplay.

The AI model is trained end to end to understand complex scene semantics such as characters, hair, fabric and translucent skin, along with environmental lighting conditions like front-lit, back-lit or overcast — all by analyzing a single frame. DLSS 5 then uses its deep understanding to generate visually precise images that handle complex elements such as subsurface scattering on skin, the delicate sheen of fabric and light-material interactions on hair, all while retaining the structure and semantics of the original scene.

DLSS 5 provides game developers with detailed controls for intensity, color grading and masking, so artists can determine where and how enhancements are applied to maintain each game’s unique aesthetic. Integration is seamless, using the same NVIDIA Streamline framework used by existing DLSS and NVIDIA Reflex technologies.

Availability and Game Developer Support

DLSS 5 will be supported by the industry’s biggest publishers and game developers, including Bethesda, CAPCOM, Hotta Studio, NetEase, NCSOFT, S-GAME, Tencent, Ubisoft and Warner Bros. Games.

“Bethesda has such a rich history pushing graphics with NVIDIA, going all the way back to Morrowind, with that incredible water,” said Todd Howard, studio head and executive producer at Bethesda Game Studios. “When NVIDIA showed us DLSS 5 and we got it running in Starfield, it was amazing how it brought it to life. We’ve played it. We can’t wait for all of you to do so as well.”

“At CAPCOM, we strive to create experiences that feel cinematic, compelling and deeply believable — where every shadow, texture and ray of light is crafted with intention to enhance atmosphere and emotional impact,” said Jun Takeuchi, executive producer and executive corporate officer at CAPCOM. “DLSS 5 represents another important step in pushing visual fidelity forward, helping players become even more immersed in the world of Resident Evil.”

“Immersion is about making the world feel real. DLSS 5 is a real step towards that goal,” said Charlie Guillemot, co-CEO of Vantage Studios. “The way it renders lighting, materials and characters changes what we can promise to players. On Assassin’s Creed Shadows, it’s letting us build the kind of worlds we’ve always wanted to.”

DLSS 5 will come to games including AION 2, Assassin’s Creed Shadows, Black State, CINDER CITY, Delta Force, Hogwarts Legacy, Justice, NARAKA: BLADEPOINT, NTE: Neverness to Everness, Phantom Blade Zero, Resident Evil Requiem, Sea of Remnants, Starfield, The Elder Scrolls IV: Oblivion Remastered, Where Winds Meet and more.

DLSS 5 will arrive this fall.

Watch the


GTC keynote


from Huang and explore


sessions


.

About NVIDIA


NVIDIA
(NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:

Ben Berraondo
NVIDIA Corporation
[email protected]

Certain statements in this press release including, but not limited to, statements as to: instead of approximating reality through rules, NVIDIA now training systems to understand it, unlocking a level of visual fidelity, efficiency and creative freedom it simply couldn’t achieve before; the benefits, impact, performance, and availability of NVIDIA’s products, services, and technologies; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; expectations with respect to AI and related industries; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing product and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; NVIDIA’s ability to realize the potential benefits of business investments or acquisitions; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

Many of the products and features described herein remain in various stages and will be offered on a when-and-if-available basis. The statements above are not intended to be, and should not be interpreted as a commitment, promise, or legal obligation, and the development, release, and timing of any features or functionalities described for our products is subject to change and remains at the sole discretion of NVIDIA. NVIDIA will have no liability for failure to deliver or delay in the delivery of any of the products, features or functions set forth herein.

© 2026 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, CUDA, GeForce, GeForce RTX and GTX are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated. Features, pricing, availability and specifications are subject to change without notice.

A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/83b417e4-9020-4a2f-afff-e3c482bbd300

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38thAnnual Roth Conference.

Iradimed’s CEO, Roger Susi, and CFO, Jack Glenn, will host one-on-one meetings between company management and investors at the 38th Annual Roth Conference, which will be held at the Ritz-Carlton in Laguna Niguel, CA, on March 22 and 24, 2026.

About
IRADIMED CORPORATION

IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.

We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed for use during MRI procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can cause radio-frequency interference and are dangerous to operate in the presence of the powerful magnet used in an MRI system. Our patented MRidium® MRI-compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.

Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, allowing it to operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from the critical care unit to the MRI and back, increasing patient safety through uninterrupted vital-signs monitoring and reducing the time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and an optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and enables effective communication of patient vital signs to clinicians.

For more information, please visit www.iradimed.com.

Media Contact:
Jack Glenn
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
[email protected]

BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) — GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the “BCA”) pursuant to which IBAC will acquire all of the issued and outstanding shares in the capital of GNQ by way of a statutory plan of arrangement under the Canada Business Corporations Act (the “Transaction”). Following closing of the Transaction, which is expected in the third quarter of 2026, the combined company expects to be publicly listed on Nasdaq. Shares will trade on Nasdaq under the symbol IBAC until the closing of the Transaction.

GNQ’s mission is to revolutionize drug development by leveraging artificial intelligence, digital twin technology, advanced biological modeling, and quantum computing to enable precision medicine at scale. By transforming how pharmaceutical companies discover, develop, and optimize therapeutics, GNQ empowers partners to accelerate development timelines, reduce costs, and deliver improved patient outcomes across multiple disease areas.

Rehan Huda, the Founder, Chairperson, and Chief Executive Officer of GNQ said, “Partnering with IB Acquisition Corp. marks a pivotal moment for GNQ as we scale our three comprehensive AI-powered Drug Assessment, Drug Simulation and Digital Twins Platform to transform pharmaceutical R&D and healthcare delivery. Our platforms address critical inefficiencies across the healthcare value chain, enabling smarter investment decisions and accelerating drug development to deliver truly personalized medicine.

This transaction provides the resources and public market visibility to expand our commercial partnerships and scale our solutions to serve pharmaceutical companies, investors and healthcare providers worldwide. We are excited to work with the IBAC team as we execute our vision of making precision medicine accessible and economically viable for patients worldwide.”

Al Lopez, Chief Executive Officer and Chairman of IBAC, stated, “IB Acquisition Corp. was formed with the goal of identifying a compelling partner at the forefront of innovation, and we are excited to have found that in GNQ Insilico. GNQ’s integration of Genomics, Artificial Intelligence, and Quantum Computing represents a differentiated approach to addressing the significant challenges facing drug discovery and development. We believe GNQ is well-positioned to capture meaningful market share and have great confidence in the talented GNQ team. We look forward to supporting them as they continue to execute on their vision.”

Transaction Details

The Board of Directors of each of GNQ and IBAC have approved the entering into of the BCA and the Transaction contemplated thereby. The Transaction will require the approval of the stockholders of IBAC and the shareholders of GNQ, as well as approval by the Ontario Superior Court of Justice (Commercial List). GNQ shareholders holding a majority of the GNQ shares have agreed to support the Transaction. The Transaction remains subject to customary closing conditions and is expected to close in the third quarter of 2026.

The Transaction values GNQ at US$500 million, with current GNQ shareholders having the ability to earn additional consideration through revenue earnout and share price earnout provisions. The Transaction is expected to provide approximately US$15 million in proceeds to GNQ, including a PIPE of up to US$10 million and cash held in the trust account of IBAC. Upon the closing of the Transaction, the executive officers of GNQ will become the executive officers of the combined company. The post-closing board of directors will consist of five members, including four directors designated by GNQ and one independent director designated by IBAC’s Sponsor.

Concurrently with the execution of the BCA, the Company has also entered into a letter agreement with IBAC pursuant to which the Company will complete a debt financing of convertible promissory notes (“Convertible Notes”) and common share purchase warrants for aggregate gross proceeds of up to US$2,000,000 (the “Bridge Financing”). In connection with the signing of the BCA, an investor introduced by IBAC purchased a Convertible Note for US$250,000 in aggregate principal amount. The Convertible Notes will accrue interest and may be converted at the election of the holders into common shares in the capital of GNQ.

Additional information about the proposed Transaction, including a copy of the business combination agreement and investor presentation, will be available in a Current Report on Form 8-K to be filed by IBAC with the U.S. Securities and Exchange Commission (the “SEC”) and at www.sec.gov.

Advisors

I-Bankers Securities, Inc. is acting as financial and capital markets advisor to IBAC. ArentFox Schiff LLP and Dentons Canada LLP are acting as legal advisors to IBAC.

Barnes & Thornburg LLP and Cassels Brock & Blackwell LLP are acting as legal advisors to GNQ.

About GNQ Insilico Inc.

GNQ Insilico is a pioneering TechBio company focused on improving the success of drug discovery and development through the integration of artificial intelligence and quantum computing, and advanced biological modeling to transform drug discovery and development. GNQ seeks to provide stakeholders with unprecedented insights across the drug development lifecycle through three core proprietary platforms:

	●	GNQ’s Drug Assessment Platform enables life science investors to conduct investment-grade due diligence through advanced molecular profiling, predictive toxicity assessments, and machine learning-driven efficacy predictions. The platform provides quantitative risk assessment and probability of clinical success estimation for therapeutic candidates.
	●	GNQ’s Drug Simulation Platform addresses the costly drug development process by conducting insilico clinical trials. The platform utilizes multi-omics pathway analysis, population-level response modeling, and resistance mechanism forecasting to significantly reduce development time and costs.
	●	GNQ’s Digital Twins Platform delivers personalized medicine by integrating genomic data, clinical records, proteomics profiles, and metabolic pathway analysis to create comprehensive biological digital twins. Using quantum AI-enhanced simulation, the platform enables precision treatment optimization, early disease detection, and personalized treatment planning for clinicians.

GNQ’s Drug Assessment Platform was launched in Q4-2025, with the Drug Simulation Platform and Digital Twins Platform slated for release later in 2026.

By combining these advanced AI capabilities with multi-omics integration and emerging quantum computing applications, GNQ aims to accelerate development timelines, reduce costs and support the development of more effective precision medicines across the healthcare ecosystem.

About IB Acquisition Corp.

IB Acquisition Corp. is a blank check company incorporated in Nevada and led by Chairman and Chief Executive Officer, Al Lopez. IBAC’s securities are listed on the Nasdaq Stock Market LLC under the symbols IBAC.

Additional Information

This press release relates to a proposed transaction between GNQ and IBAC. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the Transaction described herein, IBAC intends to file relevant materials with the SEC, including a registration statement on Form S-4, which will include a document that serves as a joint prospectus and proxy statement, referred to as a proxy statement/prospectus. A proxy statement/prospectus will be sent to all IBAC stockholders. IBAC will also file other documents regarding the proposed Transaction with the SEC. Before making any voting or investment decision, investors and security holders of IBAC are urged to read the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the proposed Transaction as they become available because they will contain important information about the proposed Transaction.

Investors and security holders will be able to obtain free copies of the registration statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by IBAC through the website maintained by the SEC at www.sec.gov.

The documents filed by IBAC with the SEC also may be obtained free of charge upon written request to IB Acquisition Corp., 1200 N Federal Highway, Suite 215, Boca Raton, FL 33432 or via email at [email protected].

Participants in the Solicitation

IBAC, GNQ and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from IBAC’s stockholders in connection with the proposed Transaction. A list of the names of such directors and executive officers, and information regarding their interests in the business combination and their ownership of IBAC’s securities are, or will be, contained in IBAC’s filings with the SEC. Additional information regarding the interests of those persons and other persons who may be deemed participants in the proposed Transaction may be obtained by reading the proxy statement/prospectus regarding the proposed Transaction when it becomes available. You may obtain free copies of these documents as described in the preceding paragraph.

Non-Solicitation

This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of IBAC, or GNQ, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended (the “Securities Act”).

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed Transaction between IBAC and GNQ. Such forward-looking statements include, but are not limited to, statements regarding the closing of the Transaction and IBAC’s, GNQ’s, or their respective management teams’ expectations, hopes, beliefs, intentions or strategies regarding the future. The words “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intends”, “may”, “might”, “plan”, “possible”, “potential”, “predict”, “project”, “should”, “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to assumptions, risks and uncertainties. These statements are based on various assumptions, whether or not identified in this press release. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of IBAC and GNQ. Many factors could cause actual future events to differ from the forward-looking statements in this press release, including but not limited to, (i) the risk that the Transaction may not be completed in a timely manner or at all, (ii) the failure to satisfy the conditions to the consummation of the Transaction, including the approval by the stockholders of IBAC, the satisfaction of the minimum trust account amount following any redemptions by IBAC’s public stockholders and the receipt of certain governmental and regulatory approvals, (iii) risks related to the timing, outcome and scope of review by the SEC of the registration statement on Form S-4, (iv) the inability to complete the Bridge Financing or PIPE offering, (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the business combination agreement, (vi) the outcome of any legal proceedings that may be instituted against IBAC and/or GNQ related to the business combination agreement, (vii) the ability to maintain the listing of IBAC’s stock on Nasdaq (or, if applicable, to list and maintain the listing of the combined entity on the NYSE), (viii) volatility in the price of IBAC’s securities, (ix) costs related to the Transaction and the failure to realize anticipated benefits of the Transaction, (x) the effect of the announcement or pendency of the Transaction on GNQ’s business relationships, operating results, performance and business generally, (xi) risks that the Transaction disrupts current plans and operations of GNQ, (xii) changes in the combined capital structure of IBAC and GNQ following the Transaction, (xiii) changes in the competitive industries and markets in which GNQ operates, (xiv) changes in laws and regulations affecting GNQ’s business, (xv) the ability to implement business plans and identify and realize additional opportunities, (xvi) risks related to GNQ’s projected financial information and limited operating history, (xvii) risks related to GNQ’s potential inability to achieve or maintain profitability and generate cash, (xviii) the enforceability of GNQ’s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (xix) other risks and uncertainties indicated from time to time in the filings of IBAC, including the Form S-4 Registration Statement that IBAC will file. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IBAC and GNQ assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither IBAC nor GNQ gives any assurance that either IBAC or GNQ will achieve its expectations.

Contact Information

For GNQ:

Rehan Huda
GNQ Insilico Inc.
6200 Stoneridge Mall Rd, Ste 300
Pleasanton, California 94588
[email protected]
(647) 286-0885

For IBAC:

Al Lopez
IB Acquisition Corp.
1200 N Federal Highway
Suite 215
Boca Raton, FL 33432
[email protected]
(214) 687-0020

TORONTO, March 16, 2026 (GLOBE NEWSWIRE) — Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today its selection by the UK Atomic Energy Authority (UKAEA) and Global Energy Tech company Eni to be the design and fabrication partner for the UKAEA-Eni H3AT (pronounced ‘HEAT’) Tritium Loop Facility, which is expected to be the world’s largest and most advanced tritium fuel cycle facility when it is fully commissioned in 2030.

Kinectrics brings decades of experience with tritium, a radioactive isotope of hydrogen, that is an essential fuel for future fusion power plants. This expertise includes systems engineering, safety and regulatory compliance, a vertically integrated delivery model, in-house tritium infrastructure, and existing knowledge in fusion fuel cycle systems.

This collaboration complements UKAEA’s world-leading fusion research capabilities and Eni’s experience of delivering industrial scale plants. Together, the team will accelerate innovation in tritium technologies for the UKAEA-Eni H3AT Tritium Loop Facility, a key international experimental user facility designed to lead the development of tritium technologies for fusion power plants.

Collectively, this team aims to solve challenges in the design, manufacturing, testing and delivery of fusion fuel cycles, to develop safe and commercially viable fusion energy. The recovery and reuse of tritium will be central to the supply and generation of the fuel in future fusion power plants.

As the design and fabrication partner, Kinectrics will utilize its specialized facilities and experts at the Toronto headquarters to support UKAEA and Eni with developing and integrating critical tritium-handling technologies, including:

• Atmospheric Detritiation System (ADS): Recovers tritium from gas waste streams to minimise release to the atmosphere
• Water Detritiation System (WDS): Recovers tritium from tritiated water
• Gloveboxes: Containing developmental equipment, each glovebox is unique and requires high-performing containment to safely handle tritium and protect workers from contamination.

The Government of Canada recently announced investments of up to $15 million from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) and Natural Resources Canada (NRCAN) to support Kinectrics’ public-private collaboration on the UK Atomic Energy Authority–Eni H3AT loop tritium facility.

Nisa Halsey, vice president of Nuclear Equipment and Tooling at Kinectrics, said:

“As the fusion industry matures, the H3AT facility will become critical infrastructure to optimize the fusion fuel cycle. Kinectrics brings decades of experience as an OEM of specialized equipment for the fission industry and expertise in supplying complex isotopic process systems through rigorous engineering and manufacturing excellence. The Kinectrics team is proud to collaborate with outstanding, global partners like UKAEA and Eni to deliver the H3AT Tritium Loop Facility and support the advancement of fusion energy technology.”

Sarah Clark, Director of Tritium Fuel Cycle Division at UKAEA and UKAEA-Eni H3AT Tritium Loop Facility sponsor, said:

“We are delighted that Kinectrics will join our integrated project team as the H3AT Tritium Loop Facility’s fabrication partner. Having the right partners is essential for H3AT’s design and development to be successful, and Kinectrics’ experience with tritium, fusion and adjacent sectors complements what we already have from UKAEA and Eni. This multinational collaboration will further develop Culham Campus and the UK more widely as an unrivalled location for fusion energy research and development.”

Francesca Ferrazza, Head of Magnetic Fusion Initiatives, Eni, said:

“Eni supports the development of fusion energy as a breakthrough in the energy transition path. This international partnership reinforces the status of the H3AT facility bringing together world class experts to meet crucial technical objectives related to the tritium fuel cycle and extends Eni’s commitment to the industrialization of fusion energy.”

The Honourable Evan Solomon Minister of Artificial Intelligence and Digital Innovation and Minister responsible for the Federal Economic Development Agency for Southern Ontario, said:

“Southern Ontario’s world-class resources, manufacturers, innovators and skilled workforce continue to set our country apart as a leader in the clean energy economy. This investment in Kinectrics will advance cutting-edge tritium infrastructure that supports the safe development of clean fusion energy, protects workers and communities, and positions Ontario’s growing nuclear sector for global success.”

The Honourable Tim Hodgson, Minister for Energy and Natural Resources, said:

“Supporting Kinectrics’ contribution to the UKAEA-Eni H3AT Tritium Loop Facility demonstrates how Canadian nuclear expertise and innovation are playing a key role in our government’s plan to diversify our trade relationships and be a clean energy superpower.”

The selection of Kinectrics builds on partnerships between Canada and the UK on fusion energy.

The UKAEA-Eni H3AT Tritium Loop Facility, located at Culham Campus in Oxfordshire, is expected to be complete in 2028, strengthening UKAEA’s position as the world’s leading hub for fusion energy research and development.

More information about the UKAEA-Eni H3AT Tritium Loop Facility can be found here: https://www.ukaea.org/news/eni-and-ukaea-to-build-tritium-fuel-cycle-facility/

Forward-Looking Statements

BWXT cautions that this release contains forward-looking statements, including statements relating to the performance, timing, impact and value, to the extent contract value can be viewed as an indicator of future revenues, of the contract for Kinectrics to be the fabrication partner for the UKAEA-Eni H3AT Tritium Loop Facility and the award or exercise of any contract options or orders. These forward-looking statements involve a number of risks and uncertainties, including, among other things, modification or termination of the contract and delays. If one or more of these or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risk factors, please see BWXT’s annual report on Form 10-K for the year ended December 31, 2024, and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. BWXT cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.

About Kinectrics

Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), is a category leader in providing lifecycle management services to the electricity industry. Trusted by clients worldwide, Kinectrics’ expertise in engineering, inspection, and certification is backed by a diverse array of independent laboratory and testing facilities, a fleet of field inspection equipment, and an award-winning team of over 1,300 engineers and technical experts. Kinectrics is also a trusted nuclear OEM and lifecycle partner, that provides design, manufacturing, testing, and qualification services for complex nuclear systems and equipment worldwide.

Learn more about Kinectrics

About the
UKAEA 

The United Kingdom Atomic Energy Authority (UKAEA) is the UK’s national fusion energy research organisation. We are an executive non-departmental public body of the Department for Energy Security and Net Zero (DESNZ). 

UKAEA’s mission is to lead the delivery of sustainable fusion energy and maximise the scientific and economic benefit. We do this by being technical experts, partnering with companies and the international research community. 

At the core of UKAEA’s efforts is the operation of world-leading facilities that build a comprehensive knowledge base for fusion energy. By addressing and solving the challenges across the full lifecycle of fusion, and integrating solutions from various disciplines, we establish technical centres of excellence that serve as the foundation for future fusion power plant programmes. 

UKAEA collaborates with its partners to develop fusion power plants by providing access to our skills, facilities and expertise. UKAEA owns UK Industrial Fusion Solutions (UKIFS) on behalf of the UK government. Through UKIFS, we’re spearheading the Spherical Tokamak for Energy Production (STEP) programme to design and build the UK’s first prototype fusion energy power plant in Nottinghamshire. 

To grow the fusion ecosystem, UKAEA focuses on cultivating skilled talent, growing the fusion industry and creating ‘innovation clusters’. We actively seek opportunities to advance fusion technologies and communicate its vast potential to stakeholders and the public alike to accelerate fusion energy’s future – the energy of tomorrow we need today. 

Learn more about the UKAEA

About Eni

Eni supports a just energy transition, promoting efficient and more sustainable access to energy resources. Eni places innovation at the centre of its strategic vision and it has transformed the businesses by investing significantly in research, development, and the implementation of technologies to progressively decarbonising its energy mix and achieving carbon neutrality by 2050.

Learn more about Eni

About FedDev Ontario

Since 2009, the Government of Canada, through FedDev Ontario, has worked to advance and diversify the southern Ontario economy through funding opportunities and business services that support innovation, growth and job creation in Canada’s most populous region. The Agency has delivered impressive results, which can be seen in southern Ontario businesses that are creating innovative technologies, improving productivity, growing revenues, creating jobs, and in the economic advancement of communities across the region. Learn more about the impact the Agency is having in southern Ontario by exploring our impact stories, our Southern Ontario Spotlight, and FedDev Ontario’s X, Facebook, Instagram and LinkedIn accounts.

About NRCan

Natural Resources Canada develops policies and programs that enhance the contribution of the natural resources sector to the economy, improve the quality of life for all Canadians and conducts innovative science in facilities across Canada to generate ideas and transfer technologies.

Media Contacts

Brandon Emrich
Senior Director, Strategic Marketing & Sales
Kinectrics
[email protected]

Chris Wearmouth
Technical Communications Specialist
UKAEA
[email protected]

Eni
Press Office: [email protected]

Sofia Ouslis
Press Secretary
Office of the Minister of Artificial Intelligence, Digital Innovation and Minister responsible for the Federal Economic Development Agency for Southern Ontario
[email protected]   

Charlotte Power
Office of the Minister of Energy and Natural Resources
[email protected]

ATLANTA, March 16, 2026 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC is investigating whether Hercules Capital, Inc. (“Hercules” or the “Company”) (NYSE: HTGC) complied with federal securities laws. On February 27, 2026, Hunterbrook Capital (“Hunterbook”) published a report alleging, among other things, that Hercules’ “headline credit metric may be an invention that flatters its track record” and that Hunterbrook could not identify any other major business development company that uses the same methodology for cumulative net realized loss rate. The price of the Company’s stock dropped following this news.

If you purchased Hercules stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/hercules-capital/ to discuss your legal rights.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025 dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

SYDNEY, March 16, 2026 (GLOBE NEWSWIRE) — Innovation Beverage Group Limited (NASDAQ: IBG) (the “Company”), an innovative developer, manufacturer, and marketer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands, today announced the closing of its registered public offering made on a reasonable best-efforts basis with gross proceeds to the Company of approximately $6 million, before deducting placement agent fees and other offering expenses payable by the Company.

The offering consisted of 3,428,569 Common Units (and/or Pre-Funded Units), with each consisting of (i) one (1) Ordinary Share, or one (1) Pre-Funded Warrant, (ii) one (1) Series A Warrant to purchase one (1) Ordinary Share per warrant at an exercise price of $1.75 and (iii) one (1) Series B Warrant to purchase one (1) Ordinary Share per warrant at an exercise price of $1.75. The public offering price per Common Unit was $1.75 (or $1.74999 for each Pre-Funded Unit, which is equal to the public offering price per Common Unit to be sold in the offering minus an exercise price of $0.00001 per Pre-Funded Warrant). The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering was decreased on a one-for-one basis. The initial exercise price of each Series A Warrant is $1.75 per Ordinary Share. The Series A Warrants are exercisable immediately and expire 60 months after the initial issuance date. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the registration statement on Form F-1, as amended, filed in connection with the offering. The initial exercise price of each Series B Warrant is $1.75 per Ordinary Share. The Series B Warrants are exercisable immediately and expire 60 months after the initial issuance date. The number of securities issuable under the Series B Warrant is subject to adjustment as described in more detail in the registration statement on F-1 filed in connection with the offering.

Aggregate gross proceeds to the Company were approximately $6 million. The transaction closed on March 16, 2026. The Company intends to use $2,500,000 of the net proceeds to make a non-interest bearing loan to Blockfuel in order for Blockfuel to exercise its call right pursuant to the Common Stock Purchase Agreement dated as of December 24, 2025, by and among Blockfuel and the investors thereto. The Company intends to use the remaining net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. acted as the exclusive placement agent for the offering. Sichenzia Ross Ference Carmel LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel to Aegis Capital Corp.

A registration statement on Form F-1 (No. 333-294127) previously filed with the U.S. Securities and Exchange Commission (the “SEC”) was declared effective by the SEC on March 12, 2026. The offering was made only by means of a prospectus. A final prospectus describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at [email protected], or by telephone at +1 (212) 813-1010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Innovation Beverage Group Limited

Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 60 formulations across 13 alcoholic and non-alcoholic brands for which it owns exclusive manufacturing rights. Focused on premium and super premium brands and market categories where it can disrupt age old brands, IBG’s brands include Australian Bitters, BITTERTALES, Drummerboy Spirits, Twisted Shaker, and more. IBG’s most successful brand to date is Australian Bitters, which disrupted a 200-year-old market leader, giving the Company a market dominating position in several territories including a partnership in Australia with Coca-Cola Europacific Partners. Established in 2018, IBG’s headquarters, distillery, innovation, and manufacturing facility are located in Sydney, Australia with a U.S. sales office in California. For more information visit: https://www.innovationbev.com/

Forward-Looking Statements

The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Contact:

Innovation Beverage Group Limited

Sahil Beri
CEO
[email protected]
www.innovationbev.com

Investor Relations:

KCSA Strategic Communications
Philip Carlson, Managing Director
T: 212-896-1233
[email protected]

ALMATY, Kazakhstan, March 16, 2026 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”, or the “Company”) (Nasdaq: KSPI) today announced that the Company has filed its Annual Report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission (the “SEC”).

Kaspi.kz’s 2025 Annual Report on Form 20-F is available on the investor relations section of its website at https://ir.kaspi.kz/financial-information/ and on the SEC’s website at www.sec.gov.

About Kaspi.kz

Kaspi.kz’s mission is to improve people’s lives by developing innovative mobile products and services. To deliver upon this we operate a unique two-sided Super App model – Kaspi.kz Super App for consumers and Kaspi Pay Super App for merchants.

Through these Super Apps consumers and merchants can access our leading Payments, Marketplace, and Fintech Platforms. All our services are designed to be highly relevant to users’ everyday needs and enable consumers and merchants to connect and transact between themselves.

The combination of a large, highly engaged consumer and merchant base, best-in-class, highly relevant digital products and a capex lite approach, results in strong top-line growth, a profitable business model and enables us to continue innovating, delighting our users and fulfilling our mission.

In Türkiye Kaspi.kz owns an 85.17% stake in Hepsiburada, one of the country’s leading e-commerce companies.

Harvard Business School has written two case studies on Kaspi.kz which it continues to teach to its MBA students.

Kaspi.kz has been listed on Nasdaq since January 2024.

For further information

David Ferguson, [email protected] +44 7427 751 275